Navigation Links
Nuvelo Reports Second Quarter 2008 Financial Results
Date:7/23/2008

target="_new">http://www.nuvelo.com.

The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at http://www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (http://www.streetevents.com), a password-protected event management site.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy- induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.

This press release contains "forward-looking statements," which include statements regarding the timing, progress and anticipated completion of Nuvelo's clinical stage and research programs, the potential benefits that patients may experience from the use of our clinical stage compounds, and our anticipated use of cash, which statements are hereby identified as "forward- looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... New York (PRWEB) July 22, 2014 ... world. The heat produced by controlled fission chain reaction ... This steam pressure is used to drive a power- ... approximately 19% of the world’s total electricity production. Nuclear ... to several under construction, planned and proposed nuclear reactor ...
(Date:7/22/2014)... 22, 2014 The DNA Spectrum ... concise visual representation of history, migration, and culture. ... regaled by family history stories stemming from Europe. His ... "old country." Pictures and 8mm home movies painted an ... the family, and Steve ordered a test from DNA ...
(Date:7/22/2014)... SHENZHEN , Kina, 22. juli 2014 /PRNewswire/ ... et datterselskab af BGI, verdens største genomics-organisation, annoncerede ... exome-sekvenseringstjeneste baseret på Complete Genomics brancheførende platform. ... for at levere patenterede sekvenseringsteknologier med 99,999 % ... blev købt af BGI i 2013. Mere end ...
(Date:7/22/2014)... July 22, 2014 Hussey Copper , ... 29 antimicrobial copper announces Pullman Regional Hospital,s conversion ... EPA-registered antimicrobial solid touch surface, at a nominal cost.  ... MRSA, E-coli and other bacteria within 2 hours of exposure ... against bacteria and infectious diseases in its facilities. ...
Breaking Biology Technology:Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 2DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 4BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3
... Activity and ... -, - Results Presented at the 20th EORTC-NCI-AACR Symposium on Molecular ... Targets and Cancer Therapeutics -, GENEVA and ... presentation of new data from an,ongoing Phase 1-2 clinical trial demonstrating that the ...
... 20th EORTC-NCI-AACR Symposium -, SOUTH SAN ... Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), ... positive incremental data from,its ongoing Phase 2 ... and prednisone as first-line therapy for metastatic,hormone-refractory ...
... Group Corporation,("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical ... owned Japanese subsidiary, has,entered into a binding letter ... First Section Index: 4514) for the commercialization of,the ... an oral emergency contraceptive "morning after pill",which is ...
Cached Biology Technology:Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 4Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer 2Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer 3Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer 4Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer 5Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R)) 2
(Date:7/22/2014)... of planthopper known as Conosimus, which now includes six ... the southern part of the Iberian Peninsula in the ... in the open-access Journal of Insect Science ... Conosimus baenai , has been named after Manuel Baena, ... of Iberian Hemiptera. , Conosimus baenai differs ...
(Date:7/21/2014)... Millar , a professor of entomology and ... at the University of California, Riverside, has been ... International Society of Chemical Ecology ( ISCE ). , ... is the society,s highest honor. It is awarded ... chemical ecology, the study of chemicals that mediate interactions ...
(Date:7/21/2014)... monitor seals, every movement, researchers have shown for the ... offshore wind farms and pipelines. Those man-made structures probably ... to a study published in the Cell Press journal ... "I was shocked when I first saw the stunning ... an offshore wind farm in the United Kingdom, says ...
Breaking Biology News(10 mins):UC Riverside entomologist receives international honor for chemical ecology contributions 2Seals forage at offshore wind farms 2
... release is available in German . , ... by the Alfred Wegener Institute for Polar and Marine ... for the first time. Polarstern left the port of ... southern course and is located right in the Northwest ...
... the Wildlife Conservation Society, Smithsonian Tropical Research Institute, National ... a new species of fisha grouper that reaches more ... 1,000 pounds. This newly discovered species can be found ... Was the massive fish hiding among the ...
... New phase 2 data published today in The ... demonstrates activity in nonsense-mutation cystic fibrosis (CF). The ... significant improvements in the chloride channel function of patients ... the Hadassah Hebrew University Hospital in Jerusalem, Israel and ...
Cached Biology News:RV Polarstern on its way to East Siberian Sea 2RV Polarstern on its way to East Siberian Sea 3Genetics reveals big fish that almost got away 2PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet 2PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet 3
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
NATIVE, ENZYME PORCINE TRYPSIN...
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
EDTA, disodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99.0-101.0%, nuclease-free.Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemi...
Biology Products: